Simplex Trading’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-8,000
| Closed | -$8K | – | 8366 |
|
|
2025
Q3 | $8K | Buy |
+8,000
| New | +$1.1K | ﹤0.01% | 8000 |
|
|
2024
Q2 | – | Sell |
-800
| Closed | -$1K | – | 8650 |
|
|
2024
Q1 | $1K | Buy |
+800
| New | +$966 | ﹤0.01% | 8514 |
|
|
2023
Q3 | – | Sell |
-23,200
| Closed | -$21K | – | 8532 |
|
|
2023
Q2 | $21K | Sell |
23,200
-500
| -2% | -$596 | ﹤0.01% | 6702 |
|
|
2023
Q1 | $25K | Buy |
+23,700
| New | +$36.7K | ﹤0.01% | 6654 |
|
|
2022
Q3 | – | Sell |
-2,200
| Closed | -$3K | – | 9787 |
|
|
2022
Q2 | $3K | Sell |
2,200
-3,600
| -62% | -$6.18K | ﹤0.01% | 9097 |
|
|
2022
Q1 | $11K | Buy |
5,800
+4,900
| +544% | +$13.2K | ﹤0.01% | 8772 |
|
|
2021
Q4 | $3K | Sell |
900
-8,500
| -90% | -$38.7K | ﹤0.01% | 9783 |
|
|
2021
Q3 | $40K | Hold |
9,400
| – | – | ﹤0.01% | 7777 |
|
|
2021
Q2 | $40K | Buy |
9,400
+9,159
| +3,800% | +$44.5K | ﹤0.01% | 7913 |
|
|
2021
Q1 | $127K | Buy |
241
+150
| +165% | +$859 | ﹤0.01% | 5406 |
|
|
2020
Q4 | $49K | Buy |
91
+88
| +2,933% | +$478 | ﹤0.01% | 6191 |
|
|
2020
Q3 | $2K | Sell |
3
-598
| -100% | -$5.23K | ﹤0.01% | 7377 |
|
|
2020
Q2 | $601K | Buy |
601
+556
| +1,236% | +$3.49K | ﹤0.01% | 2694 |
|
|
2020
Q1 | $12K | Buy |
+45
| New | +$149 | ﹤0.01% | 6330 |
|
|
2019
Q2 | – | Sell |
-20
| Closed | -$8K | – | 7002 |
|
|
2019
Q1 | $8K | Buy |
20
+10
| +100% | +$47 | ﹤0.01% | 6258 |
|
|
2018
Q4 | $5K | Buy |
+10
| New | +$74 | ﹤0.01% | 6184 |
|
Other funds holding ADAP
Simplex Trading's ADAP Position: Q1 2026 in Review
Simplex Trading sold out of Adaptimmune Therapeutics (ADAP) in Q1 2026, closing a stake of 18,610 shares — an estimated $483 sold.
Simplex Trading first reported a position in ADAP in Q2 2017 and held it in 25 quarters. The position peaked at $181K in Q1 2021. 1 fund tracked by Wall St. Rank holds ADAP as of Q1 2026.
- Simplex Trading reported no remaining Adaptimmune Therapeutics position as of Q1 2026 after selling out during the quarter.
- Simplex Trading sold 18,610 Adaptimmune Therapeutics shares in Q1 2026, an estimated $483.
- Simplex Trading first reported a position in Adaptimmune Therapeutics in Q2 2017 and held it in 25 quarters.
- Simplex Trading's Adaptimmune Therapeutics position peaked at $181K in Q1 2021.
- 1 fund tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2026.
Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.